Pharmaceuticals company RPG Life Sciences announced Q4FY26 results Q4FY26 Financial Highlights: Revenue from Operations: Rs 17,689 lakh in Q4FY26, up by 23.62% compared to Rs 14,309 lakh in Q4FY25 (YoY) and down by 1.74% from Rs 18,003 lakh in Q3FY26 (QoQ). Profit before exceptional items and tax: Rs 3,910 lakh in Q4FY26, up by 56.40% compared to Rs 2,500 lakh in Q4FY25 (YoY) and up by 4.16% from Rs 3,754 lakh in Q3FY26 (QoQ). Net Profit for the period: Rs 2,990 lakh in Q4FY26, a decrease of 74.52% compared to Rs 11,735 lakh in Q4FY25 (YoY) and an increase of 35.11% from Rs 2,213 lakh in Q3FY26 (QoQ) Total Comprehensive Income: Rs 2,998 lakh in Q4FY26 compared to Rs 11,620 lakh in Q4FY25 (YoY) and Rs 2,145 lakh in Q3FY26 (QoQ). FY26 Financial Highlights: Revenue from Operations: Rs 70,752 lakh in FY26, a growth of 8.28% compared to Rs 65,343 lakh in FY25. Profit before tax: Rs 15,420 lakh in FY26, down by 33.79% compared to Rs 23,288 lakh in FY25. Net Profit for the year: Rs 11,517 lakh in FY26, down by 37.15% compared to Rs 18,324 lakh in FY25. Earnings Per Share (EPS): Basic and Diluted EPS for FY26 stood at Rs 69.64 compared to Rs 110.80 in FY25. Business Highlights Dividend: The Board of Directors recommended a final dividend of Rs 24 per equity share (300%) of face value Rs 8 each for FY26, subject to shareholder approval. Acquisitions/Mergers: On December 15, 2025, the Board approved the transfer of the API division to its wholly-owned subsidiary, RPG Active Pharma Limited. Exceptional Items (FY26): Insurance Claim: A net income of Rs 2,475 lakh was recognized for the year as an insurance settlement related to a fire incident at the Navi Mumbai plant. Labour Code Impact: An incremental impact on provisions for employee benefits of Rs 1,169 lakh was recognized due to changes in the wage definition under the New Labour Codes. Impairment: A write-off of Rs 916 lakh for an intangible asset under development was recorded as the Company does not expect future economic benefits to flow from it. Ashok Nair, Managing Director, RPG Life Sciences, said: “Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands. The resilience demonstrated by our API business during the year reflects the strength of our teams and the robustness of our operations. Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness. We are also working towards widening our global footprint across fast-growing markets.” Result PDF